Prokidney (PROK) Total Non-Current Liabilities (2021 - 2026)
Prokidney (PROK) reported Total Non-Current Liabilities of $28.6 million for Q1 2026, down 19.01% year-over-year from $35.3 million in Q1 2025, and down 15.13% quarter-over-quarter from $33.7 million in Q4 2025.
Prokidney (PROK) Total Non-Current Liabilities (2021 - 2026) Analysis & Trends
Prokidney (PROK) has 6 years of Total Non-Current Liabilities data on file, last reported at $28.6 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $28.6 million, down 19.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.6 million (down 19.01% YoY), and the FY2025 annual result was $33.7 million, down 12.87% from the prior year.
- Total Non-Current Liabilities slipped to $28.6 million in Q1 2026 per PROK's latest filing, from $33.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $38.7 million in Q4 2024 and troughed at $11.6 million in Q3 2022.
- A 5-year average of $26.5 million and a median of $28.6 million in 2026 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities surged 124.18% in 2023, then fell 19.01% in 2026.
- A 5-year view of Total Non-Current Liabilities shows it stood at $12.8 million in 2022, then surged by 124.18% to $28.6 million in 2023, then jumped by 35.05% to $38.7 million in 2024, then dropped by 12.87% to $33.7 million in 2025, then fell by 15.13% to $28.6 million in 2026.
- Business Quant data shows PROK's Total Non-Current Liabilities at $28.6 million in Q1 2026, $33.7 million in Q4 2025, and $32.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Prokidney | 259.01 Mn | 1.55 Bn | - | 28.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 28.61 Mn |
| Dec 31, 2025 | 33.71 Mn |
| Sep 30, 2025 | 32.31 Mn |
| Jun 30, 2025 | 31.78 Mn |
| Mar 31, 2025 | 35.32 Mn |
| Dec 31, 2024 | 38.69 Mn |
| Sep 30, 2024 | 30.55 Mn |
| Jun 30, 2024 | 26.23 Mn |
| Mar 31, 2024 | 24.16 Mn |
| Dec 31, 2023 | 28.65 Mn |
| Sep 30, 2023 | 23.10 Mn |
| Jun 30, 2023 | 26.78 Mn |
| Mar 31, 2023 | 13.75 Mn |
| Dec 31, 2022 | 12.78 Mn |
| Sep 30, 2022 | 11.56 Mn |
| Dec 31, 2021 | 13.38 Mn |